Loratadine Articles
US HMO wins price cuts from S-P, Aventis
14 July 2000
Pfizer leads 1st-qtr US physician detailing
11 July 2000
Opponents of Claritin bill claim Senate win
5 July 2000
Pfizer/UCB battle with S-P over Zyrtec
26 May 2000
Schering-Plough net income rises 16.5%
26 April 2000
Andrx files for generic Claritin in USA
29 February 2000
Aventis takes on US antihistamine market with once-daily Allegra
29 February 2000
Stock Commentary New York
24 February 2000
Schering-Plough to reveal full desloratadine data shortly
17 February 2000
Mail pharmacy sues state Attorney General
14 February 2000
US Senators withdraw backing for S1172
28 January 2000
VP Gore's role in 1983 drug patent moves
26 January 2000
Stock Commentary New York
20 January 2000
UCB expecting 20% earnings rise for 1999
15 December 1999
US Senate committee postpones S 1172
24 November 1999
Allegra superior to Claritin on QOL scores
18 November 1999
US Vice President Al Gore supports faster approval of generics
11 November 1999
S-P seeking FDA/European OK for Claritin follow-up
28 October 1999
Schering-Plough strong sales boost EPS
22 October 1999
Stock Commentary New York
30 September 1999
US Senator withdraws backing for S 1172
29 September 1999
Don't ignore Hispanics in US pharma market
7 September 1999
World's top-selling drugs; 2002 forecasts
13 August 1999
Anti-S 1172 campaign underway in three states
4 August 1999
GW, S-P push steroids for allergic rhinitis
7 July 1999
Koop "an S-P lobbyist," says Public Citizen
7 July 1999
Hismanal withdrawn in face of competition
24 June 1999
Coalition opposes patent extension bill
15 June 1999
US DTC Rx ad spend hit $1.3 billion in 1998
25 May 1999
W-L and S-P in merger talks, says Bloomberg
25 May 1999
Schering-Plough fights to extend Claritin patent
20 May 1999
Morepen gets approval for generic loratadine
12 May 1999
Third-party payers lead Rx payments
5 May 1999
Schering-Plough sues Copley over Claritin
29 March 1999
Schering-Plough heads S&P 500 health co list
29 March 1999
R-P's ebastine "better than Claritin"
5 March 1999
Sepracor tops analysts' biotech stocks
20 January 1999
DTC ads "will top $1 billion in 1998"
5 January 1999
DTC advertising "creates conflict"
21 December 1998
FDA/Consumers Drug Interactions Campaign
27 November 1998
Schering-Plough Invest In New Belgian Plant
12 November 1998
US 2nd-Qtr Rx DTC Spending Rises 25%
6 November 1998
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
Generics Makers Slam S-P Moves To Protect Claritin
12 October 1998
Stock Commentary
24 September 1998
Pfizer's Zyrtec Tops DTC Ad Spending In May
16 September 1998
Solid Growth Forecast For Schering Plough
24 August 1998
Review Of US Second Qtr & Implications For Euro Firms
20 August 1998
US Rx DTC Ad Spend Set To Beat $1 Billion Again
28 July 1998
Solid 2nd Qtr For Schering-Plough
22 July 1998
US DTC Ad Spending "To Grow 50% This Year"
13 July 1998
Schering-Plough Still Impressing Analysts
9 July 1998
USA's Most-Dispensed Rx Drugs In April 1998
20 May 1998
US Quarterly Financial Results Round-Up
23 April 1998
Changing Scene For Drugmakers In USA
14 April 1998
Analysts Forecast Bright Outlook For US Majors
8 April 1998
Merck's Singulair In Hay Fever?
19 March 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
Managed Care's Favorite Drug Firms
28 January 1998
Drug Cos Must Act Now To Ensure Future Prosperity
22 January 1998
3rd-Qtr Rx Drug Prices Up 2.9%, Generics Fall 6.4%
25 November 1997
Drug Promo Meetings "Up 61% Since 1995"
27 October 1997
US 3rd Quarter Results Show Strong Growth
22 October 1997
US DTC Advertising Is Fastest Growing Promotional Segment
21 October 1997
Shanghai S-P Expects Strong Sales Growth
15 October 1997
GW's Zantac Knocked Off Top US Rx Drug Spot
4 September 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
Schering-Plough In Singapore
19 May 1997
Forex Impacts Sales At Pfizer, Merck And S-P
22 April 1997
S-P's Nasonex Cleared In First Markets
21 April 1997
Schering-Plough: Facility In Mexico
10 March 1997
US Rx Drug Sales For 1996 Up 10% At $85.35 Billion
24 February 1997
S-P Rapped Over Claritin Ads
17 February 1997
Significant Increases For US Drug Firms In 1996
3 February 1997
FDA Year-End Approval Spate As Expected
6 January 1997
R-PR's Nasacort "Better Than" S-P's Claritin
18 November 1996
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
